Comparative Pharmacology
Head-to-head clinical analysis: LOMANATE versus MOTOFEN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LOMANATE versus MOTOFEN.
LOMANATE vs MOTOFEN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
LOMANATE is a combination of diphenoxylate (a peripheral opioid receptor agonist that slows GI motility) and atropine (an anticholinergic that discourages abuse).
Combination of diphenoxylate (opioid agonist) and atropine (anticholinergic). Diphenoxylate acts on μ-opioid receptors in the gut to slow peristalsis and reduce fluid secretion; atropine is added to discourage abuse by causing unpleasant anticholinergic effects at high doses.
100 mg orally twice daily
1 to 2 tablets orally every 6 hours as needed, not to exceed 8 tablets per day.
None Documented
None Documented
Terminal elimination half-life is 18-24 hours in adults with normal renal function; prolonged to 40-60 hours in severe renal impairment (CrCl < 30 mL/min), requiring dose adjustment.
Terminal elimination half-life: 20-24 hours; clinical context: once-daily dosing recommended
Primarily renal (80% as unchanged drug and metabolites); biliary/fecal (15%); 5% eliminated via other routes.
Renal: ~60%; Fecal/Biliary: ~40%
Category C
Category C
Antidiarrheal
Antidiarrheal